Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 11, 2024European Journal Of HaematologyOpen Access

Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAnke GerhardtCenter for HIV and HepatogastroenterologySDSteffen DörfelOnkozentrum DresdenHSH. SchulzPraxis für Hämatologie und Onkologie

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gerhardt et al. (2024) studied this question.

synapsesocial.com/papers/68e79983b6db64358770a1ffhttps://doi.org/10.1111/ejh.14186
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Segmentation of health-care consumers: psychological determinants of subjective health and other person-related variables2020 · 42 citations
  2. 2First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study2023 · 24 citations
  3. 3A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib2022 · 25 citations
  4. 4<i>TP53</i> aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics2018 · 159 citations
  5. 5Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia2014 · 1,651 citations